Intravenous Ketamine Effects on Functional Neuroanatomy
NCT04205890 · Neurological Associates of West Los Angeles
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
fMRI T1 baseline
Measured over Images to be acquired 7 days prior to Ketamine intervention
fMRI T1 post-intervention comparison
Measured over Images to be acquired at 2 days post-treatment
Arterial Spin Labeling (fMRI) baseline
Measured over Images to be acquired 7 days prior to Ketamine intervention
Arterial Spin Labeling (fMRI) post-intervention comparison
Measured over Images to be acquired at 2 days post-treatment
fMRI Resting Bold baseline
Measured over Images to be acquired 7 days prior to Ketamine intervention
fMRI Resting Bold post-intervention comparison
Measured over Images to be acquired at 2 days post-treatment
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Neurological Associates of West Los Angeles | Santa Monica | California | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT04205890 on ClinicalTrials.gov →
Last updated in the registry 2020-06-01. Registry records change; this page reflects the data build of 2026-08-25.
Related